GlassScriptPhysician profile
Joann Buonomano
NPI 1427022292
$1,170.05
in general payments reported to CMS, 2019-2025
17 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.06 · 2020: $15.52 · 2021: $141 · 2022: $80.05 · 2023: $394 · 2024: $372 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.77 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Baxter Healthcare | $120.60 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Novo Nordisk INC | $83.12 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $77.19 | 2024-2025 | |
| Gilead Sciences, INC. | $72.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.89 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $42.14 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $38.80 | 2024 | Fanapt |
| Sunovion Pharmaceuticals INC. | $29.58 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.34 | 2023 | Injectafer |
| Coopersurgical, INC. | $20.09 | 2022 | |
| Biogen, INC. | $19.66 | 2024 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $19.40 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $18.31 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.10 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.75 | 2024 | Airsupra |
| Abbott Laboratories | $14.17 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Buonomano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.